Stay updated on Pembrolizumab for Refractory Esophageal Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    Revision history updated from v3.4.1 to v3.4.2.
    Difference
    0.1%
    Check dated 2026-02-11T11:37:04.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1 in the page metadata, with no changes to study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-04T10:16:28.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    Changes are minor UI/footer and metadata updates (glossary toggle, QC criteria label, FEAR Act references, and version string) that do not affect core study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T06:01:31.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The page revision updated from v3.3.3 to v3.3.4, and no clinical study information or user-facing functionality is affected.
    Difference
    0.1%
    Check dated 2026-01-14T03:04:14.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    Added a new Locations section with Massachusetts sites; removed the Massachusetts Locations subsection and the HHS Vulnerability Disclosure link, and updated the page version from v3.3.2 to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T17:20:58.000Z thumbnail image
  8. Check
    96 days ago
    Change Detected
    Summary
    Revision: v3.3.2 is now shown replacing v3.2.0; this is a minor admin update with no changes to study content, eligibility criteria, outcomes, or contacts; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T20:54:08.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Refractory Esophageal Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page.